BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice.
Recently, we have shown that MK-886 - an inhibitor of five lipoxygenase activating protein (FLAP) inhibits atherosclerosis in apolipoprotein E / LDL receptor - double knockout mice. We, therefore, wanted to find out if other FLAP inhibitor - BAYx1005 given at a dose of 1.88 mg per 100 mg of body weight per day during 16 weeks, could also attenuate atherogenesis. In apoE/LDLR - DKO mouse model BAYx1005 inhibited atherogenesis, measured both by "en face" method (23.84 +/- 2.7% vs. 15.16 +/- 1.4%) and "cross-section" method (497236 +/- 31516 microm(2) vs. 278107 +/- 21824 microm(2)). This is the first report that shows the effect of BAYx1005 on atherogenesis in gene-targeted mice.
Jawień
J
J
Chair of Pharmacology, Jagiellonian University School of Medicine, Cracow, Poland. mmjawien@cyf-kr.edu.pl
Gajda
M
M
Olszanecki
R
R
Korbut
R
R
D000818:Animals; D001011:Aorta / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D001057:Apolipoproteins E / Q000235:genetics* / Q000378:metabolism; D050197:Atherosclerosis / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D001391:Azo Compounds / Q000737:chemistry; D005260:Female; D016859:Lipoxygenase Inhibitors / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D015394:Molecular Structure; D011804:Quinolines / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D011973:Receptors, LDL / Q000235:genetics* / Q000378:metabolism; D013194:Staining and Labeling / Q000379:methods
D001057:Apolipoproteins E; D001391:Azo Compounds; D016859:Lipoxygenase Inhibitors; D011804:Quinolines; D011973:Receptors, LDL; C079315:2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid; C011049:oil red O